Tagged with M&A

Novartis Richard Francis, CEO of Sandoz will step down at the end of the March. The abrupt announcement will fan the flames of rumours that parent company Novartis is planning a spinoff or sale for its generics arm.   This is a multi-year journey which I cannot commit to and therefore…

Ipsen Following on from Johnson & Johnson’s acquisition of Actelion in January 2017 and Takeda’s takeover of Shire two years later, pharma multinationals’ rush to snap up rare disease specialists continues with Ipsen’s proposed acquisition of Clementia Pharmaceuticals. Industry insiders predict that this trend is set to continue well into the…

Rare Diseases In the run-up to Rare Disease Day 2019, David H. Crean, PhD, Managing Director for Objective Capital Partners, reviews the investment and deal activity for orphan drugs in 2018 and delves into future forecasts for the rare disease space.   With drugs currently available for only about 5% of rare diseases,…

France Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service hospital partner in the French healthcare system. Additionally, Søndergaard offers his assessments of the conditions of market access in France…

Opinion Christoph Bieri, PhD is Managing Partner of Kurmann Partners, an M&A firm advising Pharma and MedTech companies on strategic mid-market deals in Europe and the Americas. In this article, Bieri looks back on the stand out deals of 2018 and gives his insights into 2019.   Sentiment in the industry is…

France Franck Hamalian, general manager of the French affiliate of Aspen, a specialty and branded multinational pharmaceutical company from South Africa, discusses the Group’s unique business model which revolves around strategic acquisitions and strong productive capabilities. Additionally, he describes the French ecosystem regarding key topics such as big data and market…

Turkey Funda Gücer, country manager at Mylan Turkey, portrays her experience in introducing the company to the Turkish market. She provides her expert insights into current trends in the Turkish generics market and reinforces her company’s commitment to providing quality, affordable treatments.   I think that Turkey is one of the…

Spain Carlos Rubió, executive president of Laboratorios Rubió, gives an overview of the company’s early years and his priorities now to make the company a larger player on the international scene. Furthermore, he highlights the need to increase the company´s size through JVs, possible M&As and US expansion, as well as…

UK The two Big Pharma giants today announced the merger between their consumer healthcare businesses, with the joint venture (JV) set to become the global market leader in over-the-counter (OTC) products with a market share of 7.3 percent.   This move will see GSK effectively split into two separate businesses –…

USA David H. Crean, PhD, Managing Director for Objective Capital Partners, a leading investment banking advisory firm examines the venture investment activity in life sciences for the past year.    In order to have a successful life sciences R&D program, biotech and pharma companies must develop game-changing therapeutics, companion diagnostics and personalized…

Opinion Christoph Bieri, PhD is Managing Partner of Kurmann Partners, an M&A firm advising Pharma and MedTech companies on strategic mid-market deals in Europe and the Americas. Here he looks at Novartis’ bold M&A moves and what they could mean for their generics arm, Sandoz.   Besides the large business platform…

Japan Takeda’s proposed acquisition of Shire may have come as a surprise to many commentators, but the appointment of an audacious French CEO in the form of Christophe Weber had already set the tone for the radical transformation upon which the Japanese company has embarked in its dual quest for internationalisation…